Washington, D.C., Medicare Reimbursement and Health Policy Director Anna Howard and San Francisco associate Sally White wrote an article for BNA’s Pharmaceutical Compliance Monitor titled, “The Next Four Years: A Prescription for Change.”

Anna and Sally outline the numerous challenges for the pharmaceutical industry posed by the new presidential term, including the establishment of health insurance exchanges, the FDA’s process of developing a pathway for the approval of biosimilars in the United States market, and looming budget concerns.

They say that, “Now more than ever the pharmaceutical industry must keep an eye on Washington and the ever-changing political and regulatory landscape – and be prepared to respond and adapt as necessary.

To read the entire article, click here.


Source: Pharmaceutical Compliance Monitor